IP Library › Granted Patent US 12,459,999
Granted Patent B2
US 12,459,999 · App. 18/062,619 · Granted Nov 4, 2025

Matrix metalloprotease-cleavable and serine protease-cleavable substrates and methods of use thereof

Inventors: Stephen James Moore (Danville, CA); Margaret Thy Luu Nguyen (San Francisco, CA); Daniel Robert Hostetter (Palo Alto, CA); Olga Vasiljeva (Cupertino, CA); Jason Gary Sagert (San Mateo, CA); Jonathan Alexander Terrett (Cupertino, CA); James William West (Bend, OR)
Assignee: CYTOMX THERAPEUTICS, INC.
C07K16/28A61K38/05A61K47/6849A61K47/6851A61K49/0058C07K7/08C07K14/00C07K16/2863C07K16/2896C07K16/40A61K2039/505A61K2039/507C07K2317/51C07K2317/515C07K2317/92C07K2319/50C07K2319/74
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,459,999
App. No.
18/062,619
Granted
Nov 4, 2025
Kind
B2
Abstract

The invention relates generally to polypeptides that include at least a first cleavable moiety (CM1) that is a substrate for at least one matrix metalloprotease (MMP) and at least a second cleavable moiety (CM2) that is a substrate for at least one serine protease (SP), to activatable antibodies and other larger molecules that include these polypeptides that include at least a CM1 that is a substrate for at least one MMP protease and at least a CM2 that is a substrate for at least one SP protease, and to methods of making and using these polypeptides that include at least a CM1 that is a substrate for at least one MMP protease and at least a CM2 that is a substrate for at least one SP protease in a variety of therapeutic, diagnostic and prophylactic indications.

Claims (8)

1. An isolated polypeptide comprising a cleavable moiety (CM), wherein the CM comprises the amino acid sequence ISSGLLSGRSANPRG (SEQ ID NO: 469).

2. The isolated polypeptide of claim 1 , further comprising an antibody or antigen binding fragment thereof (AB).

3. The isolated polypeptide of claim 2 , wherein the antigen binding fragment thereof is selected from the group consisting of a Fab fragment, a F(ab′) 2 fragment, a scFv, and a scAb.

4. A composition comprising the isolated polypeptide of claim 1 and a pharmaceutically acceptable carrier.

5. An isolated polypeptide comprising a cleavable moiety (CM), wherein the CM comprises the amino acid sequence AVGLLAPPGGTSTSGRSANPRG (SEQ ID NO: 3).

6. The isolated polypeptide of claim 5 , further comprising an antibody or antigen binding fragment thereof (AB).

7. The isolated polypeptide of claim 6 , wherein the antigen binding fragment thereof is selected from the group consisting of a Fab fragment, a F(ab′)2 fragment, a scFv, and a scAb.

8. A composition comprising the isolated polypeptide of claim 5 and a pharmaceutically acceptable carrier.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 3, 2025
From: MOORE, STEPHEN JAMES; NGUYEN, MARGARET THY LUU; HOSTETTER, DANIEL ROBERT; VASILJEVA, OLGA; SAGERT, JASON GARY; TERRETT, JONATHAN ALEXANDER; WEST, JAMES WILLIAM
To: CYTOMX THERAPEUTICS, INC.
Reel/Frame 072466/0170 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 20, 2023
From: MOORE, STEPHEN JAMES; NGUYEN, MARGARET THY LUU; HOSTETTER, DANIEL ROBERT; VASILJEVA, OLGA; SAGERT, JASON GARY; TERRETT, JONATHAN ALEXANDER; WEST, JAMES WILLIAM
To: CYTOMX THERAPEUTICS, INC.
Reel/Frame 064643/0593 →
Continuity (7)
Division 17360809 · Jun 28, 2021
Division 15002131 · Jan 20, 2016
Provisional Application 62278713 · Jan 14, 2016
Provisional Application 62277771 · Jan 12, 2016
Provisional Application 62258015 · Nov 20, 2015
Provisional Application 62105490 · Jan 20, 2015
Related Publication 20230212283A1 · Jul 6, 2023
References Cited (252)
US 3773919A · Boswell · 1973 [cited by applicant]
US 4485045A · Regen · 1984 [cited by applicant]
US 4522811A · Eppstein et al. · 1985 [cited by applicant]
US 4544545A · Ryan et al. · 1985 [cited by applicant]
US 5013556A · Woodle et al. · 1991 [cited by applicant]
US 5030719A · Umemeto et al. · 1991 [cited by applicant]
US 5151510A · Stec et al. · 1992 [cited by applicant]
US 6551795B1 · Rubenfield et al. · 2003 [cited by applicant]
US 6558728B1 · Poulsen et al. · 2003 [cited by applicant]
US 7276497B2 · Chari et al. · 2007 [cited by applicant]
US 7439319B2 · Smith et al. · 2008 [cited by applicant]
US 7442159B1 · Riechmann et al. · 2008 [cited by applicant]
US 7465790B2 · Waldmann et al. · 2008 [cited by applicant]
US 7666817B2 · Daugherty et al. · 2010 [cited by applicant]
US 7935785B2 · Smith et al. · 2011 [cited by applicant]
US 8513390B2 · Stagliano et al. · 2013 [cited by applicant]
US 8518404B2 · Daugherty et al. · 2013 [cited by applicant]
US 8524220B1 · Bermudes · 2013 [cited by applicant]
US 8529898B2 · Daugherty et al. · 2013 [cited by applicant]
US 8541203B2 · Daugherty et al. · 2013 [cited by applicant]
US 8563269B2 · Stagliano et al. · 2013 [cited by applicant]
US 8809504B2 · Lauermann · 2014 [cited by applicant]
US 9120853B2 · Lowman et al. · 2015 [cited by applicant]
US 9127053B2 · West et al. · 2015 [cited by applicant]
US 9169321B2 · Daugherty et al. · 2015 [cited by applicant]
US 9309510B2 · La Porte et al. · 2016 [cited by applicant]
US 9453078B2 · Stagliano et al. · 2016 [cited by applicant]
US 9562073B2 · Moore et al. · 2017 [cited by applicant]
US 10059762B2 · Stagliano et al. · 2018 [cited by applicant]
US 10077300B2 · Daugherty et al. · 2018 [cited by applicant]
US 10118961B2 · Stagliano et al. · 2018 [cited by applicant]
US 10138272B2 · Moore et al. · 2018 [cited by applicant]
US 10179817B2 · Sagert · 2019 [cited by examiner]
US 10233244B2 · Sagert · 2019 [cited by examiner]
US 10336824B2 · West et al. · 2019 [cited by applicant]
US 10513558B2 · Tipton · 2019 [cited by examiner]
US 10669337B2 · Irving et al. · 2020 [cited by applicant]
US 10669339B2 · West et al. · 2020 [cited by applicant]
US 10745481B2 · West · 2020 [cited by examiner]
US 10875913B2 · Stagliano et al. · 2020 [cited by applicant]
US 11028126B2 · Moore et al. · 2021 [cited by applicant]
US 11267896B2 · Sagert · 2022 [cited by examiner]
US 11753466B2 · West · 2023 [cited by examiner]
US 20030219402A1 · Rutter · 2003 [cited by applicant]
US 20040109855A1 · Waldmann et al. · 2004 [cited by applicant]
US 20040123343A1 · La Rosa et al. · 2004 [cited by applicant]
US 20050208602A1 · Rosen et al. · 2005 [cited by applicant]
US 20070218074A1 · Man · 2007 [cited by applicant]
US 20080166375A1 · Leppla et al. · 2008 [cited by applicant]
US 20090304719A1 · Daugherty et al. · 2009 [cited by applicant]
US 20100041588A1 · Keay et al. · 2010 [cited by applicant]
US 20100189651A1 · Stagliano et al. · 2010 [cited by applicant]
US 20100221212A1 · Stagliano · 2010 [cited by applicant]
US 20110214205A1 · Dietrich et al. · 2011 [cited by applicant]
US 20110280908A1 · Leppla et al. · 2011 [cited by applicant]
US 20110287517A1 · Steward et al. · 2011 [cited by applicant]
US 20120149061A1 · Stagliano et al. · 2012 [cited by applicant]
US 20120207756A1 · Stagliano et al. · 2012 [cited by applicant]
US 20120237512A1 · Daugherty et al. · 2012 [cited by applicant]
US 20120237977A1 · Daugherty et al. · 2012 [cited by applicant]
US 20120244154A1 · Daugherty et al. · 2012 [cited by applicant]
US 20120321626A1 · Zhou et al. · 2012 [cited by applicant]
US 20130078201A1 · Daly et al. · 2013 [cited by applicant]
US 20130150558A1 · Williams et al. · 2013 [cited by applicant]
US 20130266568A1 · Brinkmann et al. · 2013 [cited by applicant]
US 20130309230A1 · Stagliano et al. · 2013 [cited by applicant]
US 20140010810A1 · West et al. · 2014 [cited by applicant]
US 20140023664A1 · Lowman et al. · 2014 [cited by applicant]
US 20140024810A1 · Stagliano et al. · 2014 [cited by applicant]
US 20140045195A1 · Daugherty et al. · 2014 [cited by applicant]
US 20140255313A1 · Vasiljeva et al. · 2014 [cited by applicant]
US 20140363430A1 · West et al. · 2014 [cited by applicant]
US 20150005477A1 · Lowman et al. · 2015 [cited by applicant]
US 20150087810A1 · Moore et al. · 2015 [cited by applicant]
US 20160122425A1 · Daugherty et al. · 2016 [cited by applicant]
US 20160194399A1 · Irving · 2016 [cited by applicant]
US 20160228546A1 · Stagliano et al. · 2016 [cited by applicant]
US 20160311903A1 · West et al. · 2016 [cited by applicant]
US 20160355587A1 · West et al. · 2016 [cited by applicant]
US 20160355592A1 · Sagert et al. · 2016 [cited by applicant]
US 20160355599A1 · Sagert · 2016 [cited by applicant]
US 20170044259A1 · Tipton et al. · 2017 [cited by applicant]
US 20170081397A1 · Stagliano et al. · 2017 [cited by applicant]
US 20170204139A1 · Moore et al. · 2017 [cited by applicant]
US 20180303952A1 · Sagert et al. · 2018 [cited by applicant]
US 20190016814A1 · Humphrey et al. · 2019 [cited by applicant]
US 20190119370A1 · Stagliano et al. · 2019 [cited by applicant]
US 20190135864A1 · Moore et al. · 2019 [cited by applicant]
US 20190211089A1 · Daugherty et al. · 2019 [cited by applicant]
US 20190359714A1 · Tipton et al. · 2019 [cited by applicant]
US 20190382493A1 · West et al. · 2019 [cited by applicant]
US 20210284721A1 · Stagliano et al. · 2021 [cited by applicant]
BR 112017001579A2 · 2017 [cited by applicant]
EP 1523503B1 · 2009 [cited by applicant]
EP 1324771B1 · 2011 [cited by applicant]
JP 2010536370A · 2010 [cited by applicant]
JP 2012506408A · 2012 [cited by applicant]
JP 2012514982A · 2012 [cited by applicant]
TW 200635946 · 2006 [cited by applicant]
WO 1994011026A2 · 1994 [cited by applicant]
WO WO199915563A1 · 1999 [cited by applicant]
WO WO200157182A2 · 2001 [cited by applicant]
WO WO200191798A2 · 2001 [cited by applicant]
WO WO200212475A2 · 2002 [cited by applicant]
WO WO200230460A2 · 2002 [cited by applicant]
WO 2002038796A3 · 2002 [cited by applicant]
WO WO2003004681 · 2003 [cited by applicant]
WO WO2003038083A1 · 2003 [cited by applicant]
WO WO2003068934 · 2003 [cited by applicant]
WO WO2004009638A1 · 2004 [cited by applicant]
WO WO2006110599A2 · 2006 [cited by applicant]
WO WO2007047995 · 2007 [cited by applicant]
WO WO2007105027A1 · 2007 [cited by applicant]
WO WO2008052187A1 · 2008 [cited by applicant]
WO WO2008083312 · 2008 [cited by applicant]
WO WO2008149143 · 2008 [cited by applicant]
WO WO2008149147 · 2008 [cited by applicant]
WO WO2008149148 · 2008 [cited by applicant]
WO WO2008149149 · 2008 [cited by applicant]
WO WO2008149150 · 2008 [cited by applicant]
WO WO2009025846A2 · 2009 [cited by applicant]
WO 2010046628A1 · 2010 [cited by applicant]
WO WO2010081173A2 · 2010 [cited by applicant]
WO WO2010088691A2 · 2010 [cited by applicant]
WO WO2010091122 · 2010 [cited by applicant]
WO WO2010096838A2 · 2010 [cited by applicant]
WO WO2010129609A2 · 2010 [cited by applicant]
WO WO2011028698A2 · 2011 [cited by applicant]
WO WO2011151426 · 2011 [cited by applicant]
WO WO2011161260 · 2011 [cited by applicant]
WO 2012156919A1 · 2012 [cited by applicant]
WO WO2012158818 · 2012 [cited by applicant]
WO WO2013003649 · 2013 [cited by applicant]
WO WO2013163631A2 · 2013 [cited by applicant]
WO WO2013192546A2 · 2013 [cited by applicant]
WO WO2013192550A2 · 2013 [cited by applicant]
WO WO2014026136A2 · 2014 [cited by applicant]
WO 2014052462A2 · 2014 [cited by applicant]
WO WO2014107599A2 · 2014 [cited by applicant]
WO WO2014176284A1 · 2014 [cited by applicant]
WO WO2014193973A2 · 2014 [cited by applicant]
WO WO2014197612 · 2014 [cited by applicant]
WO 2015048329A2 · 2015 [cited by applicant]
WO 2015116933A2 · 2015 [cited by applicant]
WO 2016014974A2 · 2016 [cited by applicant]
WO 2016118629A1 · 2016 [cited by applicant]
WO WO2016149201A2 · 2016 [cited by examiner]
WO WO2016179335 · 2016 [cited by applicant]
WO 2016179257A2 · 2016 [cited by applicant]
WO WO2016210447 · 2016 [cited by applicant]
WO WO2020077267 · 2020 [cited by applicant]
WO 2020118109A2 · 2020 [cited by applicant]
Baldrick P. “Pharmaceutical excipient development: the need for preclinical guidance.” Regul. Toxicol Pharmacol. (2000) 32(2):210-218. [cited by applicant]
Bowie et al., “A method to identify protein sequences that fold into a known three-dimensional structure”, Science (1991) 253(5016):164-170. [cited by applicant]
Charman WN, “Lipids, lipophilic drugs, and oral drug delivery-some emerging concepts.” J. Pharm. Sci. (2000) 89(8):967-978. [cited by applicant]
Chen et al, “Selective Antibody Activation Through Protease-Activated Pro-Antibodies that Mask Binding Sites with Inhibitory Domains”, Scientific Reports, (2017) 7(1): 11587 (1-12). [cited by applicant]
Chothia & Lesk, “Canonical Structures for the Hypervariable Regions of Immunoglobulins”, J. Mol. Biol. (1987) 196:901-917. [cited by applicant]
Chothia et al., “Conformations of immunoglobulin hypervariable regions”, Nature (1989) 342:877-883. [cited by applicant]
Database EMBL, Accession No. OVF07168 (Jun. 15, 2017) “Clavispora lusitaniae hypothetical protein” Durrens et al. [online]; XP055665684, Retrieved from Internet on Feb. 23, 2021 (2 pages): https://www.ebi.ac.uk/ena/brow… [cited by applicant]
Database UNIPROTKB, Accession No. A0A0D8BN56 (Jun. 17, 2020) “Uncharacterized protein from Frankia torreyi”, Oshone et al. [online]; UniProt Consortium, www.uniprot.org; Retrieved from Internet on Feb. 23, 2021 (1 page)… [cited by applicant]
Database UNIPROTKB, Accession No. T0RF53 (Oct. 13, 2013), “Uncharacterized protein from Saprolegnia diclina”, Russ et al [online]; UniProt Consortium, www.uniprot.org; Retrieved from Internet: https://www.uniprot.org/un… [cited by applicant]
Davies et al., “Antibody-antigen complexes”, Annual Rev. Biochem. (1990) 59:439-473. [cited by applicant]
Eppstein et al., “Biological activity of liposome-encapsulated murine interferon gamma is mediated by a cell membrane receptor”, Proc. Natl. Acad. Sci. USA, (1985) 82(11):3688-3692. [cited by applicant]
Hwang et al., “Hepatic uptake and degradation of unilamellar sphingomyelin/cholesterol liposomes: a kinetic study”, Proc. Natl Acad. Sci. USA (1980) 77(7):4030-4034. [cited by applicant]
Jansen et al., “Immunotoxins: hybrid molecules combining high specificity and potent cytotoxicity”, Immunological Reviews (1982) 62:185-216. [cited by applicant]
Killen and Lindstrom, “Specific killing of lymphocytes that cause experimental autoimmune myasthenia gravis by ricin toxin-acetylcholine receptor conjugates”, J. Immunol. (1984) 133(5):2549-2553. [cited by applicant]
Kukreja at al., “The High Throughput Multiplexed Peptide-Centric Profiling Illustrates Both the Substrate Cleavage Redundancy and Specificity in the MMP Family”, Chem. Biol., (2015) 22(8):1122-1133. [cited by applicant]
LaPlanche et al., “Phosphorothioate-modified oligodeoxyribonucleotides. III. NMR and UV spectroscopic studies of the Rp-Rp, Sp-Sp, and Rp-Sp duplexes, [d(GGSAATTCC)]2, derived from diastereomeric O-ethyl phosphorothioat… [cited by applicant]
Malmqvist M., “Biospecific interaction analysis using biosensor technology”, Nature (1993) 361(6408):186-187. [cited by applicant]
Marasco et al., “Design, intracellular expression, and activity of a human anti-human immunodeficiency virus type 1 gp120 single-chain antibody”, Proc. Natl. Acad. Sci. USA (1993) 90(16):7889-7893. [cited by applicant]
Martin et al., “Irreversible coupling of immunoglobulin fragments to preformed vesicles. An improved method for liposome targeting”, J. Biol. Chem. (1982) 257(1):286-288. [cited by applicant]
Mitra and Lawton, “Reagents for the crosslinking of proteins by equilibrium transfer alkylation”, J. Amer. Chem. Soc. (1979) 101(11):3097-3110. [cited by applicant]
Powell et al. “Compendium of excipients for parenteral formulations” PDA J Pharm Sci Technol. (1998) 52(5):238-311. [cited by applicant]
Ramakrishnan et al., “Comparison of the Selective Cytotoxic Effects of Immunotoxins Containing Ricin A Chain or Pokeweed Antiviral Protein and Anti-Thy 1.1 Monoclonal Antibodies”, Cancer Res. (1984) 44:201-208. [cited by applicant]
Scheraga, H.A., “Predicting Three-Dimensional Structures of Oligopeptides” Rev. Computational Chem., (vol. 3, K. B. Lipkowitz and D.B. Boyd (Eds.), John Wiley & Sons, Inc., Hoboken, NJ, (1992)). [cited by applicant]
Stec et al., “Automated solid-phase synthesis, separation, and stereochemistry of phosphorothioate analogs of pligodeoxyribonucleotides”, J. Am. Chem. Soc. (1984) 106(20):6077-6079. [cited by applicant]
Stein et al., “Physicochemical properties of phosphorothioate oligodeoxynucleotides”, Nucl. Acids Res. (1988) 16(8):3209-3221. [cited by applicant]
Thornton et al., “Prediction of progress at last”, Nature (1991) 354:105-106. [cited by applicant]
Takeuchi et al., “Cellular Localization of Membrane-type Serine Protease 1 and Identification of Protease-activated Receptor-2 and Single-chain Urokinase-type Plasminogen Activator as Substrates”, J. Biol. Chem. (2000) … [cited by applicant]
Uhlmann and Peyman, “Antisense Oligonucleotides: A New Therapeutic Principle”, Chemical Reviews (1990) 90(4):543-584. [cited by applicant]
Vitetta et al., “Redesigning nature's poisons to create anti-tumor reagents”, Science (1987) 238(4830): 1098-1104. [cited by applicant]
Wang W., “Lyophilization and development of solid protein pharmaceuticals”, Int. J. Pharm. (2000) 203(1-2):1-60. [cited by applicant]
Zon et al., “Phosphorothioate oligonucleotides: chemistry, purification, analysis, scale-up and future directions”, Anticancer Drug Des. (1991) 6(6):539-568. [cited by applicant]
Office Action issued on Jan. 24, 2022 in U.S. Appl. No. 17/360,754, 18 pages. [cited by applicant]
Office Action issued on Jan. 7, 2022 in U.S. Appl. No. 17/360,855, 30 pages. [cited by applicant]
Paul, Fundamental Immunology, 3rd Edition, 1993, pp. 292-295. [cited by applicant]
Rudikoff et al., “Single amino acid substitution altering antigen-binding specificity”, Proc. Natl. Acad. Sci. USA, 1982, 79(6):1979-1983. [cited by applicant]
Colman, “Effects of Amino Acid Sequence changes on antibody-Antigen Interactions”, Research in Immunology, 1994, 145:33-36. [cited by applicant]
Bendig, “Humanization of rodent Monoclonal antibodies by CDR Grafting”, Methods: A Companion to Methods in Enzymology, 1995; 8:83-93. [cited by applicant]
Khantasup et al., “Design and Generation of Humanized Single-chain Fv Derived from Mouse Hybridoma for Potential Targeting Application”, Monoclonal Antibodies in Immunodiagnosis and Immunotherapy, 2015, 34(6): 404-417. [cited by applicant]
Murphy et al., “Enhancing recombinant antibody performance by optimally engineering its format”, Journal of Immunological Methods, vol. 463, p. 127-133, 2018. [cited by applicant]
Harris JL et al. “Rapid and general profiling of protease specificity by using combinatorial fluoreogenic substrate libraries.” PNAS vol. 97(14):7754-59 (2000). [cited by applicant]
Prudova A, auf dem Keller U, Butler GS, Overall CM. Multiplex N-terminome analysis of MMP-2 and MMP-9 substrate degradomes by iTRAQ-TAILS quantitative proteomics. Mol Cell Proteomics. May 2010;9(5):894-911. doi: 10.1074… [cited by applicant]
Ratnikov et al., “Basis for substrate recognition and distinction by matrix metalloproteinases.” Proc. Natl. Acad. Sci., vol. 111(4): E4148-55 (2014). [cited by applicant]
Takeuchi T et al. “Cellular Location of Membrane-type Serine Protease 1 and Identification of Protease-activated Receptor-2 and Single-chain Urokinase-type Plasminogen Activator as Substrates.” J Biol Chem vol. 275(34):… [cited by applicant]
ADC Review, “Maytansine” [online]. Retrieved from: http://adcreview.com/adc-university/adcs-101/cytotoxic-agents/maytansine/, on Mar. 17, 2016, 4 pages. [cited by applicant]
BLAST search of SEQ ID No. 362 from U.S. Pat. No. 9,562,073 (retrieved from http://blast.ncbi.nlm.nih.gov/Blast.cgi on Mar. 17, 2016, 8 pages). [cited by applicant]
BLAST search of SEQ ID No. 363 from U.S. Pat. No. 9,562,073 (retrieved from http://blast.ncbi.nlm.nih.gov/Blast.cgi on Mar. 17, 2016, 7 pages). [cited by applicant]
BLAST search of SEQ ID No. 364 from U.S. Pat. No. 9,562,073 (retrieved from http://blast.ncbi.nlm.nih.gov/Blast.cgi on Mar. 17, 2016, 8 pages). [cited by applicant]
Casadaban et al., “Analysis of gene control signals by DNA fusion and cloning in [cited by applicant]
Donaldson, J.M. et al., “Design and development of masked therapeutic antibodies to limit off-target effects: application to anti-EGFR antibodies”, Cancer Biology & Therapy, vol. 8, No. 22, 2009, p. 2147-2152. [cited by applicant]
GenBank Accession No. ADA97619, “Sequence 28102 from U.S. Pat. No. 6,551,795” Rubenfield, 2009, 1 page. [cited by applicant]
GenBank Accession No. AEL07912.1, “conserved hypothetical protein [Xanthomonas campestris pv.raphani 756C]” [retrieved on Dec. 28, 2017]. Retrieved from internet: https://www.ncbi.nlm.nih.gov/protein/AEL07912, 1 page. [cited by applicant]
GenBank Accession No. AF099373, “protein ITFG3 [Callothinchus milii]” 2013, 1 page. [cited by applicant]
GenBank Accession No. AKP45152, “wall-associated receptor-like kinase 2 [ [cited by applicant]
GenBank Accession No. YP 005352726.1, “petG gene product (chloroplast [Ginko biloba]” [online]. [retrieved on Dec. 28, 2017]. Retrieved from the Internet:< https://www.ncbi.nlm.nih.gov/protein/YP_005352726. 1>, 1 page. [cited by applicant]
Geneseq Accession No. AAB46481, “B. brevis tyrocidin synthetase activating domain 9” [online] First entry Apr. 9, 2001, revised Sep. 11, 2003, 2 pages. [cited by applicant]
GenPept Accession No. YP_008873205 “Hypothetical protein [Pseudomonas phage PPpW-3]” Kawato et al.; submitted Dec. 9, 2013, 1 page. [cited by applicant]
Gerspach et al. “Restoration of membrane TNF-like activity by cell surface targeting and matrix metalloproteinase-mediated processing of a TNF prodrug” Cell Death and Differentiation, 2006.13:273-284. [cited by applicant]
Henikoff, S et al. (1992) “Amino acid substitution matrices from protein blocks” [cited by applicant]
Jabaiah, A. and P.S. Daugherty, “Directed evolution of protease beacons that enable sensitive detection of endogenous MTI-MMP activity in tumor cell lines” [cited by applicant]
Ke, S-H. et al. “Distinguishing the specificities of closely related proteases” J Biol Chem, Jun. 26, 1997; vol. 272, No. 26, pp. 16603-16609. [cited by applicant]
Ke, S-H. et al., “Optimal subsite occupancy and design of a selective inhibitor of urokinase”, J Biol Chem, Aug. 15, 1997; vol. 272, No. 33, pp. 20456-20462. [cited by applicant]
Kridel, S.J. et al. “Substrate hydrolysis by matrix metalloproteinase-9” J Biol Chem, Jun. 8, 2001; vol. 276, No. 23, pp. 20572-20578. Epub Mar. 14, 2001. [cited by applicant]
Liu, S. et al. “Intermolecular complementation achieves high-specificity tumor targeting by anthrax toxin”, Nature Biotechnology, vol. 23, No. 6, p. 725-730 (2005). [cited by applicant]
Lopez-Otin, C. et al. “Protease degradomics: a new challenge for proteomics”, Nature Reviews: Molecular Cell Biology, vol. 3, p. 509-519, (2002). [cited by applicant]
Rothberg, J.M. et al. “An integrated semiconductor device enabling non-optical genome sequencing” Nature. Jul. 20, 2011:475(7356):348-352. [cited by applicant]
Turk. B.E. et al. “Determination of protease cleavage site motifs using mixture-based oriented peptide libraries” Nat Biotechnol, Jul. 2001; 19(7):661-667. [cited by applicant]
Uniprot Accession No. B8J087, “Uncharacterized protein” Mar. 3, 2009, 2 pages. [cited by applicant]
Uniprot Accession No. Q9ZZR8, “Cytochrome b” May 1, 1999, 2 pages. [cited by applicant]
UniprotKB Accession No. BIFZS3 (BIFZS3_9BURK), “Major facilitator superfamily MFS_I” [online]. Retrieved from the Internet on Jul. 25, 2018 from: <https://www.ncbi.nlm.nih.gov/protein/Akp45152>, 4 pages. [cited by applicant]
Venkatesh, B. et al. (2014) “Elephant shark genome provides unique insights into gnathostome evolution”, Nature, vol. 505, No. 7482, pp. 174-179. [cited by applicant]
Villacres, E. et al. (1993) “Cloning, Chromosomal Mapping, and Expression of Human Fetal Brain Type I Adenylyl Cyclase” Genomics, vol. 16, No. 2, 1993, p. 473-478. [cited by applicant]
Waterhouse, A.M. et al. (2009) “Jalview Version 2—a multiple sequence alignment editor and analysis workbench” Bioinformatics, 25(9):1189-1191. [cited by applicant]
EMBL Database (Jan. 2, 2014) “ [cited by applicant]
Lebeau et al. (2013) “Imaging a functional tumorigenic biomarker in the transformed epithelium”, Proc. Natl. Acad. Sci. USA, 110(1):93-98. [cited by applicant]
List et al. (2005) “Deregulated matriptase causes ras-independent multistage carcinogenesis and promotes ras-mediated malignant transformation” Genes & Develop., 19:1934-1950. [cited by applicant]
Vasiljeva et al. (2019) “The Multifaceted Roles of Tumor-Associated Proteases and Harnessing Their Activity for Prodrug Activation”, Biol. Chem. [online]. Retrieved from: https://doi.org/10.1515/hsz-2018-0451 (Received … [cited by applicant]
Kopylov, A. et al. (2007) “Methods of quantitative proteomics” [cited by applicant]
“Derivative (chemistry)”, Wikipedia, a free online encyclopedia, accessed Sep. 11, 2017, 1 page. Downloaded from: https://en.wikipedia.org/w/index.php?title=Derivative (chemistry)&oldid=779855519. [cited by applicant]
Jeong K. et al. “Recombinant antibodies: Engineering and production in yeast and bacterial hosts”, Biotechnology Journal (2011), vol. 6, p. 16-27. [cited by applicant]
“Maytansinoid”, Wikipedia, a free online encyclopedia, accessed Sep. 11, 2017, 2 pages. Downloaded from: https://en.wikipedia.org/w/index.php?title=Maytansinoid&oldid=732417913. [cited by applicant]
Kridel et al., “A Unique Substrate Binding Mode Discriminates Membrane Type-I Matrix Metalloproteinase from Other Matrix Metalloproteinases”, J. Biol. Chem. (2002) 277(26): 23788-23793. [cited by applicant]
Portolano et al., Journal of Immunology, 1993, 150(3): 1993, 880-887. [cited by applicant]
GENPEPT Accession No. POC9K2, “RecName: Full=Protein MGF 110-14L; Flags: Precursor” May 5, 2009; Database DDBJ/EMBL/Genbank [ online]. Retrieved from the Internet: <https://www.ncbi.nlm.nih.gov/protein/229544532?sat=12&… [cited by applicant]
Nangia-Makker P., et al. (Dec. 15, 2007) “Galectin-3 cleavage: a novel surrogate marker for matrix metalloproteinase activity in growing breast cancers” Cancer Res, 67(24 ): 11760-11768. NIH Public Access Author Manuscr… [cited by applicant]
Zhao T. et al. (May 21, 2010) “A novel strategy to tag matrix metalloproteinasespositive cells for in vivo imaging of invasive and metastatic activity of tumor cells” J Control Release, 144(1):109-114. doi: 10.1016/j.jc… [cited by applicant]
Irving, “Probodies Empower a New Generation of Antibody Immunotherapies,” presented at Keystone Symposia on Molecular and Cellular Biology, Feb. 2015. [cited by applicant]
Gerspach et al., “Target-selective activation of a TNF prodrug by urokinase-type plasminogen activator (uPA) mediated proteolytic processing at the cell surface.” Cancer Immunol Immunother, vol. 55: 1590-1600 (2006). [cited by applicant]
Tateno, H. et al. (Jul. 24, 1998) “Isolation and Characterization ofRharnnose-binding Lectins from Eggs of Steelhead Trout ( [cited by applicant]
U.S. Office Action issued on Feb. 3, 2022 in U.S. Appl. No. 17/360,809, 28 pages. [cited by applicant]
Russian Office Action issued on Dec. 21, 2022 in RU Application No. 2020106752, 20 pages. [cited by applicant]
Japanese Office Action issued on Sep. 20, 2022 in JP Application No. 2021-016630, 7 pages. [cited by applicant]
De Groot, N., “AsnC family protein from Sedimentitalea nanhaiensis”, XP093016536, (Apr. 12, 2017), Retrieved from the Internet on Jan. 23, 2023: URL:https://rest.uniprot.org/unisave/AOA1I7CZR5?format=txt&versions=3. [cited by applicant]
GenBank: EMG45877.1, Yu et al., Mar. 6, 2013, pp. 1-2, (www.ncbi.nlm.gov/protein/ ). [cited by applicant]
GenBank: EJK72392.1, Lommer et al., Jul. 25, 2012, pp. 1-3 (www.ncbi.nlm.gov/protein/). [cited by applicant]
Juliano et al., “Differences in substrate specificities between cysteine protease CPB isoforms of Leishmania mexicana are mediated by a few amino acid changes”, Eur. J. Biochem. (2004) 271(18):3704-3714. [cited by applicant]
Liu et al., “Targeting of Tumor Cells by Cell Surface Urokinase Plasminogen Activator dependent Anthrax Toxin”, J. Biol. Chem. (2001) 276(21):17976-17984. [cited by applicant]
Neitzel, James J., “Enzyme Catalysis: The Serine Proteases”, Nature Ed. (2010) 3(9):21. [cited by applicant]
“Uncharacterized protein from Saprolegnia parasitica”, ID: A0A0678QW3_SAPPC, Uniprot: https://rest.uniprot.org/unisave/ A0A067BQW3?fom1at=txt&versions=1; Sep. 3, 2014. [cited by applicant]
Yarilin, “The Fundamentals of Immunology,” Moscow: Meditsina, 1999, pp. 171-174 (4 pages), ISBN 5-225-02755-5. [cited by applicant]
Yarmolinskaya et al., “Matrix Metalloproteinases and Inhibitors: Classification, Mechanism of Action”, J. Obstetrics and Women's Diseases (2012) 61(1):113-125. [cited by applicant]